KRAS and neoplasm: In 48 % of the analyzed cases, the mutational diagnosis was based on primary tumor samples.<h4>Conclusions</h4>High frequencies of <i>KRAS</i> and <i>GNAS</i> mutations support the proposed role as driver mutations and as potential therapy targets.